CRXT Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

$0.42
As of 05/27/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  USA
Country of incorporation:  
IPO date:  09/07/2021
Outstanding shares:  52,020,731
Average volume:  9,217,905
Market cap:   $19,403,733
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.45
PB ratio:   -0.65
PS ratio:   1.08
Return on equity:   182.78%
Net income %:   -308.81%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy